Frontiers in Endocrinology · Nov 12, 2026

Beyond Immune Evasion: A Proposed Framework Integrating Autologous Hypoimmune iPSC-Derived Islet Organoids with MSC-Mediated Vascular Engineering for Durable β-Cell Replacement in Pediatric Type 1 Diabetes

By Maria Mohammad Sameer, Maleeha Urooj Farhan, Alwasmaa Ahmed Abbas et al.

Type 1 diabetes (T1D) is among the most common chronic diseases of childhood and adolescence, and despite major advances in insulin delivery and glucose monitoring, exogenous insulin cannot replicate the precision of native islets. β-cell replacement therapies have begun to restore endogenous insulin secretion, yet durable graft survival remains elusive, constrained by three interdependent barriers: limited donor tissue, immune-mediated injury, and inadequate vascular integration after implantation. Within a renewable autologous strategy, donor dependence is substantially reduced, shifting the central pediatric challenges to recurrent autoimmunity, vascular and engraftment failure, and graft safety over decades of use. Hypoimmune engineering and mesenchymal stromal cell (MSC)-based therapies have each addressed this problem largely in isolation. Human leukocyte antigen (HLA)-editing reduces adaptive T-cell recognition of engineered β-cell grafts, but the resulting loss of HLA class I surface expression exposes the graft to natural killer (NK) cell missing-self surveillance, a vulnerability that immune evasion alone does not resolve. Throughout this review, "autologous hypoimmune" refers specifically to engineering directed at recurrent β-cell autoimmunity rather than alloimmunity: because an autologous graft is alloimmunologically matched to the recipient, HLA class I reduction is proposed here to limit recognition of β-cell autoantigens by pre-existing autoreactive cluster of differentiation 8-positive (CD8⁺) T cells. We propose an integrated autologous framework that treats immune recognition, vascular adaptation, and microenvironmental stability as biologically linked design targets. It begins with a single adipose tissue harvest supplying both the somatic source for induced pluripotent stem cell (iPSC) reprogramming and the MSC population used for pre-transplant conditioning and co-delivery. Manufacturing yield, synchronization of the two cell products, and Good Manufacturing Practice (GMP) release testing remain unresolved constraints. Younger-onset T1D is associated with a more aggressive insulitic phenotype, and grafts implanted in childhood must remain safe and functional over decades, although much of the supporting evidence derives from adult or preclinical systems. This review proposes a testable translational framework for durable β-cell replacement in children with T1D. The integrated construct remains to be experimentally validated, and should MSC-mediated protection prove insufficient, HLA class I reduction could increase rather than reduce innate immune vulnerability.

The paperJournal siteInterventions

AgingResearch.News